206 related articles for article (PubMed ID: 30938862)
1. A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.
Gupta GK; Jaffe ES; Pittaluga S
Histopathology; 2019 Aug; 75(2):282-286. PubMed ID: 30938862
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Suzuki Y; Sakakibara A; Shimada K; Shimada S; Ishikawa E; Nakamura S; Kato S; Takahara T; Asano N; Satou A; Kohno K
Pathol Int; 2019 Jan; 69(1):13-20. PubMed ID: 30601579
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Suzuki Y; Kohno K; Matsue K; Sakakibara A; Ishikawa E; Shimada S; Shimada K; Mabuchi S; Takahara T; Kato S; Nakamura S; Satou A
Cancer Med; 2020 Jul; 9(13):4768-4776. PubMed ID: 32367674
[TBL] [Abstract][Full Text] [Related]
4. Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.
Sakakibara A; Inagaki Y; Imaoka E; Ishikawa E; Shimada S; Shimada K; Suzuki Y; Nakamura S; Satou A; Kohno K
J Clin Exp Hematop; 2018 Mar; 58(1):32-35. PubMed ID: 29415979
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
9. Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.
Sakakibara A; Inagaki Y; Imaoka E; Sakai Y; Ito M; Ishikawa E; Shimada S; Shimada K; Suzuki Y; Nakamura S; Satou A; Kohno K
Pathol Int; 2019 Mar; 69(3):148-154. PubMed ID: 30688388
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.
Sun C; Jia Y; Wang W; Bi R; Wu L; Bai Q; Zhou X
Histopathology; 2019 Mar; 74(4):618-628. PubMed ID: 30286249
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
12. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
Li L; Zhang J; Chen J; Xu-Monette ZY; Miao Y; Xiao M; Young KH; Wang S; Medeiros LJ; Wang M; Ford RJ; Pham LV
Blood; 2018 Oct; 132(17):1805-1817. PubMed ID: 30209121
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of neoplastic PD-L1-positive EBV
Takahara T; Satou A; Ishikawa E; Kohno K; Kato S; Suzuki Y; Takahashi E; Ohashi A; Asano N; Tsuzuki T; Nakamura S
Virchows Arch; 2021 Mar; 478(3):541-552. PubMed ID: 32803453
[TBL] [Abstract][Full Text] [Related]
14. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological features of intravascular large B-cell lymphoma and collision tumors of five cases].
Liu J; Liu GZ; Xia L; Wang HY; Zhang XF; Liu H
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):22-28. PubMed ID: 38178742
[No Abstract] [Full Text] [Related]
17. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
Pelland K; Mathews S; Kamath A; Cohen P; Hudnall SD; Cotta CV; Xu ML
Appl Immunohistochem Mol Morphol; 2018; 26(10):e101-e106. PubMed ID: 29189264
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
Elbaek MV; Pedersen MØ; Breinholt MF; Reddy A; Love C; Clasen-Linde E; Knudsen H; Nielsen SL; Gang AO; Høgdall E; Dave S; Nørgaard P
Hematol Oncol; 2019 Oct; 37(4):375-382. PubMed ID: 31408531
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]